Betahistine bid
PreclinicalSmall molecule
Betahistine bid is one of 34 small molecule programs targeting Tinnitus. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
44 competitors in Tinnitus
#DrugCompanyPhaseTrials
1Levitra
BayerApproved
Decadron
AAspen Global Incorporated
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Pitocin
RRetrophin
Phase 3
Zulresso
BiogenPhase 2
Neurontin
VViatris Specialty LLC
Phase 2
Deanxit
RRenJi Hospital
Approved
Enbrel
IImmunex
Phase 2
Galzin
AAmerican Regent, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Betahistine bid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSolvay Pharmaceuticals